The Effect Of Vasoactıve Agents In The Treatment Of Patıents Wıth Pulmonaryarterıal Hypertensıon

Pulmonary arterial hypertension (PAH) is a rare vascular disease and associated with progressive increases of in pulmonary vascular resistance and pulmonary arterial pressure thatwhich leads to right ventricular failure and death. Idiopathic PAH, connective tissue disease, and congenital heart disea...

Full description

Saved in:
Bibliographic Details
Published inGazi tıp dergisi Vol. 21; no. 3
Main Authors Taçoy,Gülten, Boyacı,Bülent, Okyay,Kaan
Format Journal Article
LanguageEnglish
Published Gazi Üniversitesi Yayınları 01.09.2010
Subjects
Sağlık Hizmetleri
Tıp
Ankara
Türkiye
Sidenafil
Iloprost
Bosentan
Treatment
Tedavi
Sildenafil
Pulmonary Arterial Hypertension
Pulmoner Arteriyel Hipertansiyon
Online AccessGet full text

Cover

More Information
Summary:Pulmonary arterial hypertension (PAH) is a rare vascular disease and associated with progressive increases of in pulmonary vascular resistance and pulmonary arterial pressure thatwhich leads to right ventricular failure and death. Idiopathic PAH, connective tissue disease, and congenital heart disease with left to right shunts cause PAH. The diagnosis of PAH is established hemodynamically with a mean pulmonary artery pressure > 25 mmHg at rest and > 30 mmhg mmHg in exercise. PAH must be taken into consideration for in patients which with complaints of progressive dyspnea although they have no underlying pulmonary or heart disease. TransthorasicTransthoracic echocardiography and right heart catheterization are important tools for diagnosis. The treatment as current approaches for treatment are prostanoid analogues, endothelin antagonists, and PDE-inhibitors. In our report we aimed to evaluate the effect of vasoactive agents in the treatment of patients with PAH.
ISSN:2147-2092